Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet’s disease
- 15 February 2013
- journal article
- case report
- Published by Springer Nature in Rheumatology International
- Vol. 34 (6) , 857-860
Abstract
Inflammatory large-vessel vasculitis in Behçet's disease may cause life-threatening arterial aneurysms that are prone to rupture. We report a patient with Behçet's disease with right ventricular thrombus and large aneurysms of the pulmonary arteries that led to recurrent episodes of hemoptysis. Following relapses and only partial response to repeated courses of cyclophosphamide and steroids, the patient was treated with adalimumab (Humira) and is now in clinical remission for over 30 months, with regression of her pulmonary lesions. Anti-TNFα treatment is a potential therapeutic option in patients with life-threatening complications due to large-vessel vasculitis.Keywords
This publication has 19 references indexed in Scilit:
- Behçet's disease: Successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysisArthritis Care & Research, 2011
- Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.2011
- Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.2011
- Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmologyInternational Ophthalmology, 2011
- Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab.2010
- Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.2010
- Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case reportClinical Rheumatology, 2009
- Echocardiographic manifestations of Adamantiades-Behcet's diseaseEuropean Heart Journal - Cardiovascular Imaging, 2007
- Cytokine production profile in patients with Behcet's disease treated with infliximabCytokine, 2003
- Behçet's disease: a new target for anti-tumour necrosis factor treatmentAnnals of the Rheumatic Diseases, 2002